VITAL: A Pivotal Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GENE TRANSFER)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2018
At a glance
- Drugs EB 101 (Primary)
- Indications Epidermolysis bullosa
- Focus Registrational; Therapeutic Use
- Acronyms VITAL
- Sponsors Abeona therapeutics
- 06 Dec 2018 Planned initiation date changed from 1 Oct 2018 to 1 Jun 2019, according to an Abeona Therapeutics media release.
- 06 Dec 2018 According to an Abeona Therapeutics media release, the company is planning to this study later in the middle of 2019.
- 23 Aug 2018 Status changed from planning to not yet recruiting.